QNRX•benzinga•
Quoin Pharmaceuticals Filed US Patent Application For Novel Topical Formulations For Skin Diseases, Including Netherton Syndrome, Quoin's Lead Product, QRX003, Is Currently Being Tested In Four Netherton Syndrome Clinical Trials
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 25, 2025 by benzinga